12:00 AM
Aug 02, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

BiovaxID regulatory update

Accentia's Biovest International Inc. unit said FDA granted Orphan Drug designation for BiovaxID to treat mantle cell lymphoma (MCL). BiovaxID...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >